Author

Y. Du

Observed name: Yifeng Du

Institutions: Alkermes (United States), Shandong Provincial Hospital, Shandong First Medical University

Observed institutions: Alkermes (United States), Shandong Provincial Hospital, Shandong First Medical University

OpenAlex ID: A5124170807

The First Light: Efficacy and Safety of a Multi-Dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist for the Treatment of Narcolepsy Type 1

2026 · E. Mignot, I. Arnulf, et al. · Sleep Medicine · 2

Association of Cardiovascular-Kidney-Metabolic Health With Structural Brain Imaging and the Risk of Specific-Cause Dementia: A Cohort Study

2026 · Heng Zhang, Xinhui Liu, et al. · American Journal of Geriatric Psychiatry

Effect of the Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) on Quality of Life in Individuals with NT1

2026 · S. Sivam, S. Hsiao, et al. · Sleep Medicine

A Phase 2, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Alixorexton (ALKS 2680) in Patients With Idiopathic Hypersomnia: Study Design and Methods for Vibrance-3

2026 · D. Plante, R. Grunstein, et al. · Sleep Medicine

Association of sleep trajectories and depressive symptoms among rural-dwelling older adults

2026 · S. Tang, T. Zhao, et al. · Sleep Medicine

Associations of sleep characteristics with all-cause, cardiovascular, and non-cardiovascular mortality among rural Chinese older adults: A cohort study

2026 · S. Tang, J. Lu, et al. · Sleep Medicine

Works count: 6

Citation count: 2

H-index: 1

I10-index: